Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsEfficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsTreatment of Gram-positive infections in critically ill patientsAcute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating exampleHow do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.Spontaneous Bacterial Peritonitis Due to Methicillin-Resistant Staphylococcus Aureus in a Patient with Cirrhosis: The Potential Role for Daptomycin and Review of the Literature.Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases.Reply to: "The Possible Role of Anti-methicillin-resistant Staphylococus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitis".Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections.What's new in antimicrobial use and resistance in critically ill patients?Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients.Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.Considerations about the Use of a Loading Dose of Daptomycin in a Neutropenic Murine Thigh Infection Model with Methicillin-Resistant Staphylococcus aureus Infection.
P2860
Q26752922-45EAA0E8-8874-47EC-A87F-8ACA64018464Q27000445-5F1D03D4-9CB1-419A-A503-FAA2F74A8380Q27015976-D7C568B5-C399-487A-BEEC-E48D812F4D16Q30251580-05EF0C93-B9DF-4B84-B9AD-EB75607F4FCDQ33798143-09E607D1-F09D-4A33-A765-647AF790BA5FQ34894900-F49696D5-EEB7-435B-B8A9-FDF4C8F12372Q36373724-ECF40B11-BDBC-4420-964C-ADC331444DA0Q36683458-4345D023-82D7-4AE5-B45D-9D1770DB63F3Q38616293-C5E3937B-4278-436A-B143-08B518F1318DQ38644824-2BBC4E22-A135-4BDF-BED8-DA60609643E0Q38853784-F687968F-6929-4CAC-9337-62659D1EC119Q38895642-9B61C103-573B-4049-989F-553E4EE16F72Q38907793-FACCCB5C-8BE4-4572-AE93-83A58C709632Q40578434-45284435-DC49-40B0-A08B-F7C2C5FC6753Q40837646-CB18A7BD-BE6A-4C93-89FA-89BFD078F189Q40845477-6B802579-ECFA-43DD-B2B8-0420971AA2EAQ42236463-E0742B5F-B78B-4DC4-9446-0DF3C2B7F6EFQ43949662-03D0570E-E535-47B7-9570-DD29DEF345C9Q47318913-8226E1C1-2539-4441-B2C1-46ECAB353064Q47574617-2103AB73-DA4F-4CAD-BFA2-486FC7A4E110Q47609213-A6D43155-5042-4B2E-BB33-10A308F4A0E9
P2860
Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Considerations for higher dose ...... phylococcus aureus bacteremia.
@en
Considerations for higher dose ...... phylococcus aureus bacteremia.
@nl
type
label
Considerations for higher dose ...... phylococcus aureus bacteremia.
@en
Considerations for higher dose ...... phylococcus aureus bacteremia.
@nl
prefLabel
Considerations for higher dose ...... phylococcus aureus bacteremia.
@en
Considerations for higher dose ...... phylococcus aureus bacteremia.
@nl
P2093
P2860
P356
P1476
Considerations for higher dose ...... aphylococcus aureus bacteremia
@en
P2093
Andrea Novelli
Manjunath P Pai
Mario Venditti
P2860
P304
P356
10.1093/CID/CIT582
P407
P577
2013-09-17T00:00:00Z